Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as fluocinolone acetonide
Fluocinolone Acetonide/Medidur · 1 trial · 1 indication
Visual acuity is measured using ETDRS charts at 4 meters.
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Dose 0.2 ug/day Medidur implant |
| 2 | ACTIVE_COMPARATOR | Dose 0.5 ug/day Medidur implant |
| Name | Type | Description |
|---|---|---|
| Fluocinolone Acetonide/Medidur | DRUG | 0.2 ug/day implant |
Inclusion Criteria: * Patients 50 or greater * Treated with intraocular injections of Lucentis for at least 6 months and have reached a plateau, defined as 2 consecutive visits (4-6 weeks apart) with no improvement in VA (worse or within one line better) or center subfield thickening (worse or with...
Fluocinolone Acetonide/Medidur is an investigational small molecule being studied for Age Related Macular Degeneration and Diabetic Macular Edema. It is in Phase 2 clinical development for these ophthalmology indications. The drug is not approved and remains under investigation.
ANI Pharmaceuticals, Inc. (ticker: ANIP) is developing Fluocinolone Acetonide/Medidur. The company is conducting clinical trials for the drug in the United States across multiple studies.
Fluocinolone Acetonide/Medidur is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for Age Related Macular Degeneration and Diabetic Macular Edema.
Fluocinolone Acetonide/Medidur has completed three clinical trials. These include NCT00344968 and NCT00490815 for Diabetic Macular Edema, and NCT00605423 for Age Related Macular Degeneration. All trials were completed in the United States with a total enrollment of 1113 participants.
Yes, Fluocinolone Acetonide/Medidur is also known as fluocinolone acetonide. The drug is being developed by ANI Pharmaceuticals, Inc. under this alternative name in clinical trials for eye conditions.